Research Articles - Retinitis Pigmentosa
A retinal prosthesis known to many as “the bionic retina” was implanted for the first time commercially in a patient in a hospital in Pisa, Italy, on October 29. Called the Argus II Retinal Prosthesis System, it was surgically implanted by Dr. Stanislao Rizzo, director of the University
- All 12 participants in the gene therapy clinical trial for Leber congenital amaurosis (LCA) at the Children’s Hospital of Philadelphia (CHOP) have been so delighted with the vision restoration from treatment to one eye, they have been anxiously awaiting the go-ahead to have their second eye treated. Thanks to results from a Foundation-funded lab study in large animals, that will likely happen soon.
Drs. Al Maguire, Katherine High, and Jean Bennett, lead investigators on the
A Foundation-funded research team has developed a gene therapy that restored vision in mice which had lost half of their photoreceptors to autosomal recessive retinitis pigmentosa (arRP) caused by mutations in the gene PDE6α. Results of the study, led by Stephen Tsang, M.D., Ph.D., of Columbia University, were published in the journal Human
- The three-year, 90-participant clinical study will be conducted at three sites — the University of Massachusetts Medical School, the University of Utah, and the Retina Foundation of the Southwest — under the auspices of the National Eye Evaluation Research Network. The Foundation Fighting Blindness established the network to launch clinical trials of promising treatments and cures for retinal degenerative diseases. Valproic acid is the first treatment to be evaluated in the network.
Valproic acid appears to work by masking certain protein defects that can cause
At the Foundation’s meeting of Translational Research Acceleration Program (TRAP) investigators in Las Vegas earlier this week, Al Lewin, Ph.D., of the University of Florida, discussed progress in tackling the vexing problem of developing gene therapies for autosomal dominant retinal disease — specifically retinitis pigmentosa (RP) caused by mutations in the gene rhodopsin (RHO). His team’s project is funded through
A drug developed by the company QLT for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) caused by mutations in the genes RPE65 or LRAT restored visual acuity or visual field in 11 of 14 patients in a Phase 1B clinical trial. Vision improvements for a seven-day course of the drug were sustained for two years for some study participants. No serious adverse events
- Thanks to success in preclinical studies funded in part by the Foundation Fighting Blindness, the Irish biopharmaceutical company Genable Technologies has received a €5 million (equivalent to about $6.8 million) venture capital investment to advance its gene therapy for autosomal dominant retinitis pigmentosa (adRP) into a clinical trial.
A Foundation-funded investigative team led by Ruifang Sui, M.D., Ph.D., of Peking Union Medical College Hospital, has completed the first comprehensive genetic screening of a group of Chinese people with autosomal recessive retinitis pigmentosa (arRP). Results of the
The Argus II® Retinal Prosthesis System, which restores some useful vision to people blind from advanced retinitis pigmentosa, will be offered later this year at 12 clinical centers throughout the United States.
The Argus II retinal prosthesis, a device that can restore some vision to people who are blind from advanced retinitis pigmentosa (RP), has received U.S. market approval from theFood and Drug Administration (FDA). Developed by Second Sight Medical Products, the device will be available later this year in approximately 10 clinical centers across the country. In 2011, the Argus II received marketing approval in Europe. Also known as a “bionic retina,” it is currently the world’s only retinal